<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02674763</url>
  </required_header>
  <id_info>
    <org_study_id>IMGN779 0601</org_study_id>
    <nct_id>NCT02674763</nct_id>
  </id_info>
  <brief_title>Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase 1, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunoGen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunoGen, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, multicenter Phase 1 study to determine the MTD, dosing schedule and
      RP2D of IMGN779 when administered as mono-therapy to adult AML patients with CD33 -positive
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the Dose Escalation Phase, patients will be assigned to one of three schedules. The MTD
      for all schedules will be determined from the assessment of Dose Limiting Toxicities (DLTs).
      The Dose Expansion Phase will consist of one cohort based on patients response to prior
      therapy according to the MTD selected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">July 2019</completion_date>
  <primary_completion_date type="Actual">June 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of IMGN779</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent adverse events</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) (complete response [CR= CR+CRp+CRi]+partial remission [PR])</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: maximum plasma concentration (Cmax) of IMGN779</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: area under the time-concentration curve (AUC) of IMGN779</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: terminal half-life (tÂ½) of IMGN779</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Presence of Antibody-Drug Antibody (ADA)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Schedule A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMGN779 administered on days 1 and 15 of a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Schedule B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMGN779 administered on days 1, 8, 15 and 22 of a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Schedule C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMGN779 administered on days 1 and 8 of a 21-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Relapsed AML; IMGN779 administered at dose and schedule selected as the putative RP2D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMGN779</intervention_name>
    <arm_group_label>Dose Escalation Schedule A</arm_group_label>
    <arm_group_label>Dose Escalation Schedule B</arm_group_label>
    <arm_group_label>Dose Escalation Schedule C</arm_group_label>
    <arm_group_label>Dose Expansion Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dose Escalation: Patients with relapsed or refractory AML

          -  Dose Expansion: Patients with relapsed AML or patients who refuse, or are not suitable
             candidates for induction therapy

        Exclusion Criteria:

          -  Dose Escalation: Acute Promyelocytic Leukemia

          -  Any concurrent anti-cancer therapy including chemotherapy, immunotherapy,
             radiotherapy, biologic or any investigational agents (with the exception of
             hydroxyurea or leukapheresis for control of hyperleukocytosis) within 14 days or five
             half-lives of drugs, whichever is shorter, prior to Cycle 1 Day 1

          -  AML patients with known, active leptomeningeal/central nervous system (CNS)
             involvement

          -  Prior treatment with IMGN779

          -  Women who are pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Zweidler-McKay, MD</last_name>
    <role>Study Director</role>
    <affiliation>ImmunoGen, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Cancer Center (UAB CCC)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Cancer Care Alliance</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knight Cancer Institute - OSHU</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas, MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 1, 2016</study_first_submitted>
  <study_first_submitted_qc>February 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2016</study_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>IMGN779</keyword>
  <keyword>ImmunoGen</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <keyword>CD33</keyword>
  <keyword>Dose Escalation</keyword>
  <keyword>Dose Expansion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

